{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:34:55Z","timestamp":1792146895590,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1053\/j.seminhematol.2012.01.007","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T11:25:16Z","timestamp":1332588316000},"page":"128-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders"],"prefix":"10.1053","volume":"49","author":[{"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.01.007_bib1","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib2","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1182\/blood.V66.2.312.312","article-title":"Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor","volume":"66","author":"Denburg","year":"1985","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.iac.2006.05.004","article-title":"Molecular mechanisms of mast cell development","volume":"26","author":"Kitamura","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.4049\/jimmunol.148.3.772","article-title":"Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells","volume":"148","author":"Kirshenbaum","year":"1992","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib6","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1365-2222.2009.03325.x","article-title":"Haemopoietic processes in allergic disease: eosinophil\/basophil development","volume":"39","author":"Gauvreau","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.4049\/jimmunol.170.1.537","article-title":"The CCR3 receptor is involved in eosinophil differentiation and is up-regulated by Th2 cytokines in CD34+ progenitor cells","volume":"170","author":"Lamkhioued","year":"2003","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00011-009-0042-6","article-title":"Mast cells and eosinophils: the two key effector cells in allergic inflammation","volume":"58","author":"Minai-Fleminger","year":"2009","journal-title":"Inflamm Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2010.04.009","article-title":"Involvement of mast cells in eosinophilic esophagitis","volume":"126","author":"Abonia","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.humpath.2008.01.012","article-title":"Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis","volume":"39","author":"Piazuelo","year":"2008","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib12","first-page":"391","article-title":"Mast cell and eosinophil interaction in gastric carcinomas: ultrastructural observations","volume":"27","author":"Caruso","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nri2199","article-title":"Protective immune mechanisms in helminth infection","volume":"7","author":"Anthony","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/path.904","article-title":"Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique","volume":"194","author":"Jeziorska","year":"2001","journal-title":"J Pathol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib15","doi-asserted-by":"crossref","first-page":"15238","DOI":"10.1074\/jbc.M608046200","article-title":"Eotaxin selectively binds heparin","volume":"282","author":"Ellyard","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/107999004323065057","article-title":"The role of human mast cell-derived cytokines in eosinophil biology","volume":"24","author":"Shakoory","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1398-9995.1998.tb03795.x","article-title":"Release of granule proteins from human eosinophils stimulated with mast-cell mediators","volume":"53","author":"Takafuji","year":"1998","journal-title":"Allergy"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2567.2008.02916.x","article-title":"Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation","volume":"126","author":"Wong","year":"2009","journal-title":"Immunology"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib19","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.4049\/jimmunol.176.6.3788","article-title":"Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities","volume":"176","author":"Pang","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib20","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V97.4.1086","article-title":"Human peripheral blood eosinophils express stem cell factor","volume":"97","author":"Hartman","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib21","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10875-011-9589-4","article-title":"Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression","volume":"31","author":"Hudson","year":"2011","journal-title":"J Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib22","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1182\/blood-2002-10-3058","article-title":"Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis","volume":"101","author":"Nutku","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2007.10.004","article-title":"Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement","volume":"121","author":"Yokoi","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00441-010-1010-8","article-title":"Ultrastructural evidence for human mast cell-eosinophil interactions in vitro","volume":"341","author":"Minai-Fleminger","year":"2010","journal-title":"Cell Tissue Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0609.2011.01652.x","article-title":"Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma\u2014a population-based study","volume":"87","author":"Glimelius","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib26","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib27","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib28","series-title":"World Health Organization classification of tumours","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1","author":"Bain","year":"2008"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib30","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of the FIPL1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib31","first-page":"1","article-title":"Clinical features of fifteen patients with the hypereosinophilic syndrome","volume":"52","author":"Spry","year":"1983","journal-title":"Q J Med"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib32","first-page":"253","article-title":"Prognostic factors of hypereosinophilic syndrome","volume":"140","author":"Lefebvre","year":"1989","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood.V58.5.1012.1012","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome","volume":"58","author":"Flaum","year":"1981","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib34","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"The idiopathic hypereosinophilic syndrome","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib35","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood.V83.10.2759.2759","article-title":"The idiopathic hypereosinophilic syndrome","volume":"83","author":"Weller","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib36","first-page":"3","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"7","author":"Schaller","year":"2001","journal-title":"MedGenMed"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib37","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib38","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib39","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib40","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"53","article-title":"Mastocytosis","author":"Horny","year":"2008"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib41","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib42","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c-kit point mutation Asp-816 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib43","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2005.05863.x","article-title":"Multilineage involvement of the fusion gene in patients with FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"132","author":"Robyn","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib45","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1158\/0008-5472.CAN-06-4183","article-title":"Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation","volume":"67","author":"Buitenhuis","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib47","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2005-08-3153","article-title":"The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)\/chronic eosinophilic leukemia (CEL)-like disease","volume":"107","author":"Yamada","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib48","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/sj.leu.2404977","article-title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus","volume":"21","author":"Burgstaller","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib49","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood-2007-11-126268","article-title":"FIP1L1\/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia\/hypereosinophilic syndrome","volume":"112","author":"Yamada","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib50","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib52","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/cncr.25036","article-title":"Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes","volume":"116","author":"Wimazal","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib53","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2002-03-0947","article-title":"Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia","volume":"101","author":"Matsushima","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib54","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.leukres.2006.10.017","article-title":"Clinical significance of a blood eosinophilia in adult T-cell leukemia\/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor","volume":"31","author":"Utsunomiya","year":"2007","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib55","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/ijc.21688","article-title":"Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia\/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors","volume":"118","author":"Inagaki","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaad.2004.03.003","article-title":"In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia","volume":"5","author":"Ionescu","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib57","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2001.02977.x","article-title":"Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease","volume":"11","author":"Molin","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.11370","article-title":"Expression of CCL5\/rantes by Hodgkin and Reed-Sternberg cells and its possible role in the recruitement of mast cells into lymhpomatous tissue","volume":"107","author":"Fischer","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib59","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1046\/j.1365-2141.2002.03768.x","article-title":"Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma","volume":"119","author":"Molin","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib60","doi-asserted-by":"crossref","first-page":"e6341","DOI":"10.1371\/journal.pone.0006341","article-title":"Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases","volume":"4","author":"Canioni","year":"2009","journal-title":"PLoS One"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib61","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","article-title":"Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors","volume":"95","author":"von Wasielewski","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900110404","article-title":"Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis","volume":"11","author":"Enblad","year":"1993","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2007.06612.x","article-title":"Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma","volume":"138","author":"Hedstr\u00f6m","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib64","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1182\/blood-2007-11-125823","article-title":"Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP","volume":"111","author":"Taskinen","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib66","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib67","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib68","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib69","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib70","first-page":"316","article-title":"KIT inhibitor Midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial","volume":"116","author":"Gotlib","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib71","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib72","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon a-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib73","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alfa-2b","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib74","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib75","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-a: Results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon a-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib78","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib79","first-page":"661","article-title":"Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients","volume":"104","author":"Lortholary","year":"2004","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib80","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib81","first-page":"1982","article-title":"Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients","volume":"116","author":"Hermine","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib82","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib83","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib84","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib85","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib86","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib87","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib88","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"Von Bubnoff","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib89","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06221.x","article-title":"Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy","volume":"134","author":"Ohnishi","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib90","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib91","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","article-title":"Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib92","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib93","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2005-05-1932","article-title":"The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo","volume":"106","author":"Stover","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib94","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","article-title":"The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib)","volume":"107","author":"von Bubnoff","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib95","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"Cross","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib96","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib97","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.leukres.2011.10.009","article-title":"Unique association of systemic mastocytosis and myeloid\/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene","volume":"36","author":"Mayeur-Rousse","year":"2012","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.007_bib98","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631200008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719631200008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:18Z","timestamp":1758522078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719631200008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S003719631200008X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.01.007","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cells and Eosinophils in Mastocytosis, Chronic Eosinophilic Leukemia, and Non-clonal Disorders","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}